The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
You would assume that SRI are not going to waste their time partnering with a company / product unless it has a certain degree of potential for commercial success. SRI clearly like what they see with Nuvec.
It is currently difficult for N4 to showcase their product to 'big pharma' so this collaboration should make it much easier to do so.
Sounds like a great step forward for N4P.
Yep, zero debt, strong cashflow, yoy growth, love this one.
Starting to catch up... looking good.
It was a press release of the article that has been doing the rounds of late:
https://www.ophthalmologytimes.com/view/n4-pharma-moving-novel-delivery-systems-towards-commercialization
“Non-viral, non-lipid delivery systems are in high demand in the exciting gene therapy and oncology spaces and we now have two such delivery systems,” Nigel Theobald, CEO of N4 Pharma, said in the company’s news release. “Nuvec continues to show its versatility as a novel delivery system and with LipTide we are developing our first commercial product which we are aiming to take into phase 1 clinical trials.”
'The company will now engage in discussions with the FDA and MHRA to approve a GLP toxicity study and first in human clinical trials.'
Seen lots of good comments and articles in press regarding the Burberry show at London Fashion Week. Apparently Daniel Lees latest collection went down v well.